(1 - 8 von 9
)
NSCLC: Bemcentinib + anti-PD1 triple PFS - European Biotechnology
european-biotechnology.com
According to Hani Gabra, Chief Medical Officer of BerGenBio, the patients that benefited most matched gene signatures that predict poor prognosis and a lack of response to immunotherapy in NSCLC. If confirmed in larger cohorts this would qualify Bergen Bio's first-in-class AXL kinase inhibitor as effective enhancer of cancer immunotherapies.
BerGenBio to Present Top Line Translational Phase II Data With...
www.prnewswire.co.uk
Hani Gabra MD PhD, CMO BerGenBio, will provide an update of results from a phase II trial (BGBC008), evaluating bemcentinib in combination ...
sortiert nach Relevanz / Datum